GRAFT POLYMER UK LS -001 (J4I) - Cash Flow Conversion Efficiency
Based on the latest financial reports, GRAFT POLYMER UK LS -001 (J4I) has a cash flow conversion efficiency ratio of -0.048x as of November 2024. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-149.00K ≈ $-174.20K USD) by net assets (€3.08 Million ≈ $3.61 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
GRAFT POLYMER UK LS -001 - Cash Flow Conversion Efficiency Trend (2023–2025)
This chart illustrates how GRAFT POLYMER UK LS -001's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read J4I total liabilities for a breakdown of total debt and financial obligations.
GRAFT POLYMER UK LS -001 Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of GRAFT POLYMER UK LS -001 ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Kumpulan H & L High-Tech Bhd
KLSE:7033
|
0.035x |
|
S-Energy Co.Ltd
KQ:095910
|
-0.051x |
|
PPK Group Ltd
AU:PPK
|
-0.034x |
|
KNOREX LTD.
NYSE MKT:KNRX
|
N/A |
|
TURA GROUP AB
F:8WO
|
0.167x |
|
Secuve Co. Ltd
KQ:131090
|
0.065x |
|
Acco Group Holdings Limited Ordinary Shares
NASDAQ:ACCL
|
-0.123x |
|
White Energy Company Ltd
AU:WEC
|
0.030x |
Annual Cash Flow Conversion Efficiency for GRAFT POLYMER UK LS -001 (2023–2025)
The table below shows the annual cash flow conversion efficiency of GRAFT POLYMER UK LS -001 from 2023 to 2025. For the full company profile with market capitalisation and key ratios, see market cap of GRAFT POLYMER UK LS -001.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-05-31 | €3.08 Million ≈ $3.61 Million |
€-1.13 Million ≈ $-1.32 Million |
-0.366x | +40.04% |
| 2024-05-31 | €2.03 Million ≈ $2.37 Million |
€-1.24 Million ≈ $-1.45 Million |
-0.611x | -17.91% |
| 2023-05-31 | €4.55 Million ≈ $5.32 Million |
€-2.36 Million ≈ $-2.76 Million |
-0.518x | -- |
About GRAFT POLYMER UK LS -001
Solvonis Therapeutics plc, a clinical-stage biopharmaceutical company, develops novel medicines for addiction and mental health disorders. The company develops SVN-001, an NMDA receptor antagonist that is in Phase III clinical trial for the treatment of severe alcohol use disorder; and SVN-002, which has completed Phase I clinical trial to treat moderate to severe alcohol use disorder. Its pre-cl… Read more